Physician profile
Mark Wells
NPI 1497905061
$7,802.42
in general payments reported to CMS, 2019-2025
10 companies · $1,595 in 2025
The $1,595 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,344 · 2022: $1,751 · 2023: $1,745 · 2024: $1,366 · 2025: $1,595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,707.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,706.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,816.13 | 2021-2025 | Proclaim, Eterna, Lamitrode Tripole |
| Boston Scientific Corporation | $1,002.38 | 2021-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Intracept |
| Medtronic, INC. | $845.73 | 2022-2025 | Inceptiv, Vanta Adaptivestim, Intellis Adaptivestim |
| Relievant Medsystems, INC. | $447.18 | 2023 | Intracept |
| Nevro Corp. | $223.82 | 2023 | Senza |
| Grt US Holding, INC. | $193.35 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $126.82 | 2025 | Relistor |
| Tonix Medicines, INC. | $94.25 | 2025 | Tonmya |
| Takeda Pharmaceuticals U.S.A., INC. | $31.03 | 2023 | Hyqvia |
| Pacira Pharmaceuticals Incorporated | $21.73 | 2024 | Exparel, Zilretta, Iovera |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Wells listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.